Drug Profile
Etravirine - Janssen R&D Ireland
Alternative Names: Intelence; R165335; TMC-125Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Tibotec Pharmaceuticals
- Developer Janssen R&D Ireland; Janssen-Cilag; Xian-Janssen
- Class Antiretrovirals; Pyridazines; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 01 Apr 2018 French National Institute for Health and Medical Research completes a phase II trial for HIV-1 infections (Combination therapy, Treatment-experienced) in France, and Spain (NCT02212379)
- 10 Mar 2015 No recent reports on development identified - Phase-II for HIV-1 infections (Combination therapy, Treatment-naive) in USA, Australia, Austria, Belgium, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Romania, Russia, Spain, Switzerland and United Kingdom (PO)
- 16 Nov 2012 Committee for Medicinal Products for Human Use recommends approval of Etravirine for HIV-1 infections (combination therapy, in children, in adolescents, treatment-experienced patients) in EU